4D Molecular Therapeutics (FDMT)
(Delayed Data from NSDQ)
$25.28 USD
+0.03 (0.12%)
Updated Apr 22, 2024 11:56 AM ET
After-Market: $26.42 +1.14 (4.51%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Bottom 41% (147 out of 250)Zacks Sector Rank
Top 25% (4 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.10 | 1.52 | 9.99 |
Current Quarter Estimate | -0.73 | -2.04 | 60.00 |
Year Ago Quarter Estimate | -0.88 | -0.59 | 52.54 |
Next Quarter Estimate | -0.76 | -2.00 | 61.00 |
Next Year Estimate | -3.15 | 6.92 | 270.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | -17.44 | 10.20 | 17.08 |
Next Year | -3.96 | 13.80 | 8.00 |
Last 5 Years | NA | 5.90 | 8.10 |
Next 5 Years | NA | 22.10 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -5.88 |
Price/Book (MRQ) | 3.51 | 1.87 |
Price/Cash Flow (MRFY) | NA | 9.05 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -436.30% | -19.76% |
Return on Equity (TTM) | -34.14% | -72.91% |
Debt to Equity (MRQ) | NA | 0.30 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.